Novo Nordisk challenges Pfizer with a surprise $6.5 billion bid for Metsera, aiming to outbid Pfizer's earlier offer and reshape the obesity drug market.
Novo Nordisk challenges Pfizer with a surprise $6.5 billion bid for Metsera, aiming to outbid Pfizer's earlier offer and reshape the obesity drug market.